All In Biotech

Drug Trial Radar · NCT04535193

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

An Open-Label, Exploratory, Phase 1/2 Scintigraphy Study Evaluating 18F-mFBG for Imaging Myocardial Sympathetic Innervation in Subjects Without and With Heart Disease

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Actual

Start

Nov 5, 2021

Primary completion

Mar 7, 2025

Study completion Aug 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
Mount Sinai Hospital, New York
First posted
Sep 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.

Conditions

  • Cardiovascular Diseases

Interventions

  • 18F-mFBG for intravenous administrationDrug

    Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Chang in 18F-mFBG uptakeTime frame: Up to 210 minutes after dosing
  2. Evaluation of 18F-mFBG for imaging myocardial sympathetic innervationTime frame: Up to 100 minutes after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai Morningside

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.